Moneycontrol PRO

you are here: HomeNewsBusinessEarningsIntegration costs to continue into FY16: Sun Pharma

SHOW NAMES

Trending Topics

SBI Q1 Results Manappuram Finance Q1 Results Tata Motors Q1 results Titan Q1 Preview SBI Q1 Preview

business

Integration costs to continue into FY16: Sun Pharma

Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

first published: Jun 1, 2015 01:19 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347